The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy

NCT06505278 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide in the evening

Sponsor

Sun Yat-sen University